If you or a loved one has diffuse large B-cell lymphoma (DLBCL) that is no longer responding to treatment or came back after treatment, chimeric antigen receptor (CAR) T-cell therapy may be an option.

It’s called chimeric antigen receptor T-cell therapy, or CAR T-cell therapy for short. It has been approved for people who have not been helped by other treatments for DLBCL. Could you be a ...

Despite these advancements, more than 50% of patients with lymphoma do not have long-term remission with anti-CD19 CAR T-cell therapy. These patients have limited treatment options and poor prognoses.

PHILADELPHIA – A next-generation “armored” CAR T cell therapy showed promising results in a small study of patients whose B-cell lymphomas continued to resist multiple rounds of other cancer ...

Chimeric antigen receptor (CAR) T-cell therapy is an innovative cancer treatment that engineers a patient’s own T cells to target and destroy cancer cells. While the field has sparked ...

When it comes to relapsed/refractory follicular lymphoma, chimeric antigen receptor (CAR) T-cell therapy has become a go-to treatment for some patients, with its high end durable response rates ...

Investigating brain fog CAR-T cell therapy was approved for acute lymphoblastic leukemia in 2017. The treatment involves removing some of the patient's own immune cells, known as T cells, and ...

An optimized CAR-T cell therapy targeting CD30 (HSP-CAR30) demonstrated high efficacy in patients with relapsed or refractory CD30 + lymphoma, achieving a 100% overall response rate and 50–55% ...

Cognitive impairment after CAR-T cell therapy is typically mild; patients are not developing dementia, for instance. But it is frustrating and may not resolve on its own, Monje said.

Researchers at the Sant Pau Research Institute (IR Sant Pau), in collaboration with the Hospital de Sant Pau and the Josep Carreras Leukaemia Research Institute, have developed an innovative CAR-T ...

Cancer treatment with a cell-based immunotherapy causes mild cognitive impairment, a Stanford Medicine team found. They also identified compounds that could treat it. After treatment with CAR-T ...

A Phase I clinical trial, whose results have been published in the prestigious journal Blood, reveals that this new CAR-T30 therapy promotes the expansion of memory T cells, leading to long ...